Related Experiment Video
Updated: Mar 18, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease With Severe Mitral Annular Calcification:
Mayra Guerrero1, Danny Dvir2, Dominique Himbert3
1Department of Medicine, Division of Cardiology, Evanston Hospital, Evanston, Illinois.
Insights
Transcatheter mitral valve replacement (TMVR) using balloon-expandable valves is feasible for severe mitral annular calcification (MAC). While associated with adverse events, it offers an alternative for high-risk patients.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Medical Devices
Background:
- Surgical mitral valve replacement carries high risks for patients with severe mitral annular calcification (MAC).
- Transcatheter mitral valve replacement (TMVR) with balloon-expandable valves shows promise in isolated reports for this challenging patient group.
Purpose of the Study:
- To evaluate the outcomes of early transcatheter mitral valve replacement (TMVR) experiences.
- To assess the use of balloon-expandable valves in patients with severe mitral annular calcification (MAC).
- To report findings from the first large, multicenter global registry on this topic.
Main Methods:
- A multicenter retrospective review was conducted.
- Clinical outcomes of patients with severe MAC undergoing TMVR were analyzed.
- Data were collected from September 2012 to July 2015 across 32 centers.
Main Results:
- 64 patients with severe MAC underwent TMVR using balloon-expandable valves.
- Technical success was achieved in 72% of patients; 9.3% experienced left ventricular tract obstruction.
- Thirty-day all-cause mortality was 29.7%, with 84% of survivors in NYHA class I or II.
Conclusions:
- Transcatheter mitral valve replacement (TMVR) with balloon-expandable valves is feasible in severe mitral annular calcification (MAC).
- The procedure is linked to significant adverse events, necessitating careful patient selection.
- This approach may serve as a viable alternative for select high-risk individuals with limited options.
Objectives:
This study sought to evaluate the outcomes of the early experience of transcatheter mitral valve replacement (TMVR) with balloon-expandable valves in patients with severe mitral annular calcification (MAC) and reports the first large series from a multicenter global registry.
Background:
The risk of surgical mitral valve replacement in patients with severe MAC is high. There are isolated reports of successful TMVR with balloon-expandable valves in this patient population.
Methods:
We performed a multicenter retrospective review of clinical outcomes of patients with severe MAC undergoing TMVR.
Results:
From September 2012 to July of 2015, 64 patients in 32 centers underwent TMVR with compassionate use of balloon-expandable valves. Mean age was 73 ± 13 years, 66% were female, and mean Society of Thoracic Surgeons score was 14.4 ± 9.5%. The mean mitral gradient was 11.45 ± 4.4 mm Hg and the mean mitral area was 1.18 ± 0.5 cm(2). SAPIEN valves (Edwards Lifesciences, Irvine, California) were used in 7.8%, SAPIEN XT in 59.4%, SAPIEN 3 in 28.1%, and Inovare (Braile Biomedica, Brazil) in 4.7%. Access was transatrial in 15.6%, transapical in 43.8%, and transseptal in 40.6%. Technical success according to Mitral Valve Academic Research Consortium criteria was achieved in 46 (72%) patients, primarily limited by the need for a second valve in 11 (17.2%). Six (9.3%) had left ventricular tract obstruction with hemodynamic compromise. Mean mitral gradient post-procedure was 4 ± 2.2 mm Hg, paravalvular regurgitation was mild or absent in all. Thirty-day all-cause mortality was 29.7% (cardiovascular = 12.5% and noncardiac = 17.2%); 84% of the survivors with follow-up data available were in New York Heart Association functional class I or II at 30 days (n = 25).
Conclusions:
TMVR with balloon-expandable valves in patients with severe MAC is feasible but may be associated with significant adverse events. This strategy might be an alternative for selected high-risk patients with limited treatment options.
Related Concept Videos
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Stenosis I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Mitral Stenosis IV: Nursing Management

